A Trusted Partner for the Biopharmaceutical Industry and Laboratories
The Sartorius Group is a prominent partner in life science research and the biopharmaceutical industry, providing innovative laboratory instruments and consumables. Their Lab Products and Services Division aids research and quality control in pharmaceutical and biopharmaceutical companies. Meanwhile, the Bioprocess Solutions Division specializes in single-use solutions for the production of biotech medications and vaccines. The Group consistently achieves double-digit annual growth and expands by acquiring complementary technologies.
Catalog Number 4912124
Catalog Number 7192774
Catalog Number 7070833
Catalog Number 4570852
Catalog Number 4229356
Sartorius' nationwide field service network makes the installation and maintenance of all balances and moisture analyzers convenient and easy. Whether you need basic service, general installation, calibration, specific certificates or reports, count on Sartorius' factory-trained technicians to give the best service experience in the industry.
The new generation of modular precision, analytical and microbalances
Choosing the optimal ultrafiltration device
The Picus family pipettes are kind to your hand with unbeatable ergonomic design that ensures reliable and repeatable experiment results
Aruim™ Bag meets and exceeds the challenges of life in the lab
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products and Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies, as well as those of academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies.